Latest Communications

16 January 2013
MonoSol Rx Enters Into Licensing Agreement With Vestiq Pharmaceuticals for Zuplenz(R) Oral Soluble Film

19 November 2012
APR Applied Pharma Research ("APR") and Labtec GmbH ("Labtec") announce the European approval of two new Oral Dispersible Film (ODF) based respectively on Olanzapine and Donepezil

05 October 2012
Stellar Pharmaceuticals Launches New Migraine Treatment, CAMBIA®, in $150 Million Canadian Prescription Migraine Market


50 mg Diclo K IR tablet


Thanks to the Patented Immediate Release Technology (IRT) , tablets 50 mg has the following advantages compared with competing products:

> immediate release profile (Cmax in 27 min. compared to 54 min. of Voltfast)

> regularity of absorption (reduced intra-subject variability in absorption)

> cost competitive manufacturing process (dry mixing for direct compression)




Complete
Non confidential
Opportunity
Profile



Acute Pain / Migraine products

2.5 mg and 5 mg Zolmitriptan ODF
5% ww Diclo K drops
50 mg Diclo K IR sachet
50 mg Diclo K IR tablet
Diclo 50 mg IR ODT and ODP



Search results